Home › Research › How common it is
Neuro-inflammation and anti-inflammatory treatment options for Alzheimer's disease
Ozben T, Ozben S.. Clinical biochemistry, 2019-04-04
Topic: Amyloid, tau and blood-test diagnosis
Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive memory loss and dementia. The pathological characteristics of AD include the deposition of amyloid beta (Aβ), neurofibrillary tangles, and neuronal loss. There is evidence showing the involvement of inflammation in AD, including activated microglia within and surrounding senile plaques. Epidemiological studies suggest the use of anti-inflammatory drugs to reduce incidence of AD. However, clinical trials with anti-inflammatory drugs have not been successful.
Key findings
- Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive memory loss and dementia.
- The pathological characteristics of AD include the deposition of amyloid beta (Aβ), neurofibrillary tangles, and neuronal loss.
- There is evidence showing the involvement of inflammation in AD, including activated microglia within and surrounding senile plaques.
- Epidemiological studies suggest the use of anti-inflammatory drugs to reduce incidence of AD.
- However, clinical trials with anti-inflammatory drugs have not been successful.
Why it matters
This review notes that inflammation is involved in Alzheimer's disease and that epidemiological studies suggested anti-inflammatory drugs might reduce incidence, but clinical trials with these drugs have not been successful. It reports no effective anti-inflammatory treatment for Alzheimer's disease.
New to this subject? Start with our plain-English guide: Alzheimer's in numbers →
Study details
- Evidence strengthLow
How this study scored 45/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Clinical biochemistry) |
| Journal's citation record | 2 / 4 | Clinical Biochemistry: journal h-index 152 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2019 — within 10 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 6 / 7 | Cited 381 times (OpenAlex, 2026-10-10) |
| Citations per year | 4 / 5 | 42.3 citations a year over 9 year(s) since 2019 |
| Impact for its field and year | 4 / 6 | Cited 19.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 4 other studies in this library |
| Still being cited | 3 / 4 | Cited 160 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Serkan Özben: h-index 13 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | Akdeniz University: institution h-index 250 (OpenAlex) |
| Multi-centre collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 30954437) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 45 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
APA 7th
Ozben, T., & Ozben, S. (2019). Neuro-inflammation and anti-inflammatory treatment options for Alzheimer's disease. Clinical biochemistry. https://doi.org/10.1016/j.clinbiochem.2019.04.001
Vancouver
Ozben T, Ozben S. Neuro-inflammation and anti-inflammatory treatment options for Alzheimer's disease. Clinical biochemistry. 2019. doi:10.1016/j.clinbiochem.2019.04.001. PMID: 30954437.
BibTeX
@article{ozben2019-30954437,
author = {Ozben, T. and Ozben, S.},
title = {{Neuro-inflammation and anti-inflammatory treatment options for Alzheimer's disease}},
journal = {Clinical biochemistry},
year = {2019},
doi = {10.1016/j.clinbiochem.2019.04.001},
pmid = {30954437},
url = {https://doi.org/10.1016/j.clinbiochem.2019.04.001}
}
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
4 studies in the alzhub library list this one in their references.
Related studies in How common it is
Also in How common it is
80 studies in the library are filed under How common it is with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The How common it is hub.